N@N

Sernova Corp: Notice of Allowance Issued for Key Patent for Sernova's Sertoli Cell Platform

^{Published on 2009-08-31 14:51:59 - Market Wire}
 

LONDON, ONTARIO--(Marketwire - Aug. 31, 2009) - Sernova Corp. (TSX VENTURE:SVA) today announced that the Canadian Patent Office has issued a Notice of Allowance for a key patent related to its genetically modified sertoli cell platform. International patents are still pending.

The Patent, entitled "Production of a Biological Factor and Creation of an Immunologically Privileged Environment Using Genetically Altered Sertoli Cells", claims the use of Sertoli cells that have been genetically modified to produce biological factors important in the prevention and treatment of a wide range of diseases. The Notice of Allowance was issued July 13th, 2009 to Sertoli Technologies, Inc., the exclusive licensor to Sernova Corp.

"This patent adds to our extensive portfolio of over 20 issued and pending patents" said Dr. Philip Toleikis, Sernova's President and CEO. "The broad claims in this patent position Sernova with the potential to extend its Sertoli cell platform beyond our current focus of insulin-dependent diabetes to the treatment of a wide range of disorders including Parkinson's disease, blood disorders (haemophilia, hyperbilirubinemia, hemoglobinopathies such as sickle-cell disease, anaemia in chronic kidney disease, and related to cancer chemotherapy); the prevention of infection in susceptible individuals such as oncology patients, AIDS patients and those with other white blood cell diseases, as well as the prevention or treatment of certain cancers in genetically predisposed populations."

Naturally occurring Sertoli cells possess a unique ability to maintain an immune-privileged environment. In combination with Sernova's novel Cell Pouch System^TM, Sertoli cells may potentially be used in a variety of settings to eliminate the need for expensive and toxic immunosuppressive drugs. Sernova's genetically modified Sertoli cell platform combined with Sernova's novel Cell Pouch System^TM further enables the potential replacement of key natural substances in the body, or to produce therapeutic agents to prevent or treat disease.

Sernova anticipates that the expansion of its current programs will occur through a combination of internal research efforts, as well as external corporate and academic collaborations.

About Sernova

Sernova Corp. is a Canadian-based, health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System^TM and its patented Sertolin^TM cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.